TRIM24 and breast cancer: Even if rapid progress has been made in the development of new small-molecule tools targeting the PHD finger domains, selective inhibitors, i.e., targeting TRIM24, frequently overexpressed in breast cancer and associated with poor overall survival and tumor progression, have not yet been developed [48,49].